2020 Medicinal Chemistry Reviews

Volume 55, Chapter 27
To Market, to Market—2019: Small Molecules
Erika Araujo, Catherine A. Bolger, Marie-Gabrielle Braun, Georgette Castanedo, Mingshuo Zeng, Adam K. Charnley, Antonella Converso, Izzat T. Raheem, Anthony J. Roecker, Akshay A. Shah, T. G. Murali Dhar, Denise C. Grünenfelder, J. Robert Merritt, Kevin M. Peese

1. Afamelanotide (erythropoietic protoporphyria)
2. Alpelisib (anticancer)
3. Bremelanotide (hypoactive sexual desire)
4. Brexanolone (postpartum depression)
5. Cefiderocol (antibacterial)
6. Cenobamate (anticonvulsant)
7. Darolutamide (anticancer)
8. Elexacaftor (cystic fibrosis)
9. Entrectinib (anticancer)
10. Erdafitinib (anticancer)
11. Esaxerenone (hypertension)
12. Fedratinib (anticancer)
13. Fexinidazole (antiparasitic)
14. Flumatinib (anticancer)
15. Lascufloxacin (antibacterial)
16. Lasmiditan (migraine)
17. Lefamulin (antibacterial)
18. Lemborexant (insomnia)
19. Lumateperone (schizophrenia)
20. Mirogabalin (neuropathic pain)
21. Pexidartinib (anticancer)
22. Pretomanid (antibacterial)
23. Quizartinib (anticancer)
24. Relebactam (antibacterial)
25. Relugolix (uterine fibroids)
26. Remimazolam (anesthetic)
27. Remogliflozin etabonate (diabetes)
28. Selinexor (anticancer)
29. Siponimod (multiple sclerosis)
30. Solriamfetol (narcolepsy)
31. Sotagliflozin (diabetes)
32. Tapinarof (psoriasis)
33. Tenapanor (irritable bowel syndrome)
34. Triclabendazole (antiparasitic)
35. Trifarotene (acne)
36. Ubrogepant (migraine)
37. Upadacitinib (rheumatoid arthritis)
38. Voxelotor (sickle cell disease)
39. Zanubrutinib (anticancer)

To purchase a copy of this chapter, go to our secure e-commerce site.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org